INmune Bio has partnered with Cell and Gene Therapy Catapult to establish commercial-scale manufacturing for CORDStrom, a promising therapy for recessive dystrophic epidermolysis bullosa that showed positive results in Phase 2 trials.
INmune Bio presented baseline demographics from its MINDFuL Phase II trial showing 208 patients with early Alzheimer's disease and confirmed biomarkers of inflammation, with 69.2% being APOE ε4 carriers.
INmune Bio's CaRe PC trial, evaluating INKmune in metastatic castration-resistant prostate cancer (mCRPC), has expanded to the West Los Angeles VA Medical Center.
INmune Bio is advancing clinical trials for Alzheimer's disease (AD) and metastatic castrate-resistant prostate cancer (mCRPC), with promising early data for XPro in AD.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.